 | |
| Identifiers | |
|---|---|
| CAS Number | |
| Chemical and physical data | |
| Formula | C25H30F3N3O3 |
| Molar mass | 477.528 g·mol−1 |
| 3D model (JSmol) | |
| |
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans.
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets. All four laboratories were closed and sold, and no employees were retained.
The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.